Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2056 to 2070 of 9026 results

  1. Hyaluronic acid injection in periprosthetic leakage / pharyngocutaneous fistula in patients with voice prosthesis in post-laryngectomy patients

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Electrosurgery (diathermy and coblation) for tonsillectomy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. Actim Pancreatitis for diagnosing acute pancreatitis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  6. Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. NVK-002 for treating myopia in people 3 to 17 years [TSID11961]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Reinforcement of a permanent stoma with synthetic or biological mesh to prevent a parastomal hernia

    Awaiting development Reference number: GID-HTG10678 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]

    Awaiting development Reference number: GID-TA11594 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]

    Awaiting development Reference number: GID-TA11532 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

    Awaiting development Reference number: GID-TA11706 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

    Awaiting development Reference number: GID-TA11835 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development